Synthesis And Pharmacological Evaluation Of Novel Thiazole Derivatives

The design, synthesis, and assessment of novel thiazole derivatives' antibacterial properties are presented here. These compounds showed modest antibacterial activity, according to the in vitro study. Compound 3 had the highest activity, with MIC and MBC ranging from 0.25 to 0.1 and 0.49 to 0.96 mg/mL, respectively. Three compounds (b, c, and d) demonstrated greater potential than the reference medication ampicillin when tested against three resistant strains of P. aeruginosa, E. coli, and methicillin-resistant Staphylococcus aureus. The compounds' antifungal activity was superior, with MIC and MFC falling between 0.07 and 0.49 and 0.12 and 0.96 mg/mL, respectively. Compound I exhibited the highest activity, with a MIC of 0.06–0.25 mg/mL and an MFC of 0.13–0.49 mg/mL. Docking studies suggest that the compounds' antibacterial action may be due to their expected inhibition of the E. coli MurB enzyme, while their antifungal activity is most likely due to their inhibition of 14a-lanosterol demethylase.